TheraRadar
← Back
Data updated: Jun 28, 2026

B BRAUN

Specialty
Infectious DiseaseOphthalmologyDermatology Execution: Excellent

B BRAUN is a specialty pharmaceutical company focused on Infectious Disease, Ophthalmology, Dermatology. Key products include SODIUM CHLORIDE 0.9%.

1946
Since
215
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
8 Small Molecules

B BRAUN at a Glance

  • Strong track record with 92% execution quality across 13 trials
  • Fast trial execution (23 months median completion)

Upcoming FDA Decisions

Full Calendar →
Jul 26, 2026 — Tavapadon
15d
Jul 30, 2026 — Pivekimab sunirine (PVEK)
Aug 17, 2026 — Iberdomide + daratumumab/dexamethasone
+2 more dates (Pro)

B BRAUN's Key Drugs

B BRAUN's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

B BRAUN's Recent FDA Approvals

New NDA/BLA approvals for B BRAUN over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

B BRAUN's Therapeutic Areas

B BRAUN's approved drugs and pipeline span 5 therapeutic areas, led by Infectious Disease and Ophthalmology, across 0 biologic and 8 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Infectious Disease 38%
4 drugs Phase 1: 5
Ophthalmology 31%
4 drugs
Dermatology 16%
2 drugs
Metabolic 8%
1 drugs
Cardiovascular 8%
1 drugs

B BRAUN Pipeline Snapshot

B BRAUN has 5 active clinical programs from ClinicalTrials.gov — 0 Phase 3, 0 Phase 2 and 5 Phase 1.

0
Phase 3
0
Phase 2
5
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • Top drug revenue breakdown
  • • Drug-level revenue analysis

Trial Catalysts

  • • Infectious Disease pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 8/8 completed
  • • Speed: 23 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges